Physician profile
Robert Weissinger
NPI 1942287917
$968.45
in general payments reported to CMS, 2019-2025
16 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.60 · 2021: $137 · 2022: $159 · 2023: $257 · 2024: $261 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $658.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $657.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $444.84 | 2021-2025 | Qulipta, Ubrelvy |
| Bayer Healthcare Pharmaceuticals INC. | $95.70 | 2021-2025 | |
| Mylan Specialty L.P. | $88.60 | 2023-2024 | Yupelri |
| Novo Nordisk INC | $51.67 | 2021-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $48.41 | 2021-2025 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $47.87 | 2021-2024 | |
| Amgen INC. | $46.75 | 2023-2024 | Evenity, Prolia |
| Merck Sharp & Dohme LLC | $25.58 | 2021-2023 | Gardasil 9, M-M-R II, Vaxneuvance |
| Biohaven Pharmaceuticals, INC. | $20.31 | 2021 | |
| Viatris Specialty LLC | $15.92 | 2025 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $14.86 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.60 | 2019 | |
| Neurocrine Biosciences, INC. | $14.60 | 2024 | Ingrezza |
| Ultragenyx Pharmaceutical INC. | $13.75 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.22 | 2024 | Xifaxan |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $11.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Weissinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.